Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
AssigneeSepracor Inc.
InventorsPaul D. Rubin, Timothy J. Barberich
Life of this patent
Estimating the term…
Abstract
Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer.
Claims16
A method of treating apnea or an apnea disorder in a patient which comprises administering a therapeutically effective amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer, and a therapeutically effective amount of at least one other therapeutic agent selected from fluoxetine or the R or S stereoisomer thereof, norcisapride or the (+) or (−) stereoisomer thereof, ubidecarenone, dipyramole, pilocarpine or a stereoisomer thereof, primidone or the R or S stereoisomer thereof, or orphenadrine citrate.
A method of treating apnea or an apnea disorder in a patient which comprises orally administering a therapeutically effective amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer, and a therapeutically effective amount of at least one other therapeutic agent for the treatment of apnea.
A method of treating apnea or an apnea disorder in a patient which comprises parenterally administering a therapeutically effective amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer, and a therapeutically effective amount of at least one other therapeutic agent for the treatment of apnea.
Dependencies are inferred from the claim text.